Centers for Medical Countermeasures Against Radiation

描述(申请人提供)：与过去相比，对全球核战争的担忧不太可能发生，取而代之的是使用放射性武器进行恐怖袭击的真正可能性。近年来，随着全球恐怖组织活动的增加和非法贩运放射性材料的增加，此类袭击的威胁有所增加。不幸的是，很少有医疗产品可以对抗核攻击或辐射攻击可能导致的各种急性和长期毒性。仍然非常需要扩大现有的医疗选择，以预防或治疗辐射损伤。我们已经成立了一个名为辐射对策研究卓越中心(RadCCORE)的联盟，共同合作增加可能的药物，以检测、减轻和治疗那些暴露在确定剂量的辐射中的人(www.radccore.org/)。辐射生物学、健康物理学、干细胞生物学/移植和免疫学领域的顶尖科学家聚集在一起，组成了最全面、最具包容性、跨机构和跨学科的辐射医学对策中心(CMCR)。RadCCORE是一个学术医疗中心网络：杜克大学、北卡罗来纳大学和维克森林大学，将由五个研究项目和四个支持核心组成。这组调查人员的一个主要好处是他们在正常组织损伤、辐射生物学、物理学、培训和教育领域的奉献精神和力量。鉴于我们的大多数先导化合物已经通过开发管道取得进展，现在得到外部资助，我们选择了一套新的有希望的对策，但所有原始核心和核心领导都完好无损。这一安排为我们的中心带来了新的调查人员、增加的基础和翻译科学知识以及新的缓解剂。该网络涉及广泛的研究领域，并在开发新的治疗产品以防止短期和长期毒性方面取得了长足进步。

DESCRIPTION (provided by applicant): Concerns about global nuclear war, less likely than in the past, have been replaced by the real potential of a terrorist strike using radiological weapons. The threat of such attacks has grown in recent years, with the increased activity of global terrorist organizations and a rise in illicit trafficking of radioactive materials. Unfortuntely, very few medical products exist to counter the variety of acute and long-term toxicities that can result from nuclear or radiological attacks. There remains a great need to expand the medical options available to prevent or treat radiation-induced injury. We have formed a consortium termed Radiation Countermeasures Centers of Research Excellence (RadCCORE) to collectively and collaboratively increase possible agents to detect, mitigate and treat those people exposed to deterministic doses of radiation (www.radccore.org/). Leading scientists in the area of radiation biology, health physics, stem cell biology/transplantation and immunology have come together to form one of the most comprehensive, inclusive, inter-institutional, and interdisciplinary Center for Medical Countermeasures Against Radiation (CMCR). RadCCORE is a network of academic medical centers: Duke University, University of North Carolina, and Wake Forest University and will consist of five research projects and four support cores. A major benefit of this group of investigators has been the dedication and strength of the individuals in the areas of normal tissue injury, radiation biology, physics, training and education. Given that most of our lead compounds have progressed through the development pipeline and are now externally funded, we have selected a new set of promising countermeasures but with all the original cores and core leaders intact. This arrangement brings novel investigators, increased basic and translational science knowledge and novel mitigators to our center. This network addresses broad areas of research and has made great strides in the development of new therapeutic products to prevent short- and long-term toxicities.